Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

1 year ago 57

Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.

1. Homepage
2. Prostate Cancer
3. Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate